Inspire Medical Q2 2026: Guidance Held Steady, and the Stock Jumped 22.8%

The headline is "Inspire raises guidance, stock jumps 22.8%." The number underneath it is less dramatic: the new full-year revenue range, $835 million to $875 million, is barely above the bottom of the $825 million-$875 million range the company slashed its outlook to back in May — and still well short of the original $950 million-$1 billion guidance from before that cut, which triggered a 16.4% after-hours decline at the time. The market is reacting to the direction reversing, not to the number itself recovering.

What changed since May

Second-quarter revenue was $200.6 million, with diluted earnings per share of $0.01 and adjusted diluted earnings per share of $0.14. The company raised its full-year revenue guidance to $835 million-$875 million — a top end unchanged from May's cut and a bottom end lifted only modestly. Shares still jumped 14.6% to $59.85 in premarket trading and extended the gain through the day to close at $64.14, up 22.8% from Monday's close.

Why a small move in the number produced a large move in the stock

May's cut was driven by coding and reimbursement disruption that curbed procedure volumes; the open question since then has been whether that pressure was temporary or structural. A guidance range that holds steady rather than falling further is itself the evidence investors were waiting for — it suggests the disruption stopped getting worse, even though it has not yet reversed. The company's new Project Horizon plan, aimed at freeing up about $30 million in annualized growth investment capacity through restructuring, reads as confirmation that management is treating this as an extended repair job rather than a one-quarter blip.

What to watch

Whether the next guidance revision is another hold, a further raise back toward the original $950 million-plus range, or a renewed cut — that trajectory, not any single quarter's number, is what will show whether the coding disruption is actually resolving.